ArticleeLife2018
The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells.
Abstract read
In one paragraph
Article in eLife, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed.
- Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Selective estrogen receptor degraders and their effect on the breast cancer immune microenvironment.The Journal of clinical investigation · 2026Review
- Identification and Validation of the ESR1 Y537S Mutant-Enriched Enhancer and Its Downstream Target IGFBP3.Cancer research communications · 2026Article
- Targeting Estrogen Receptor for Breast Cancer.Current issues in molecular biology · 2026Review
- The properties of personal semantics.Memory & cognition · 2026Article
- Nucleic sexual hormone receptor signaling pathways in breast cancer: function regulation, crosstalk, and therapeutic implications.NPJ precision oncology · 2026Review
- Allosteric Induction of Estrogen Receptor Ligand Binding Domain Tetramerization by a Distinct Complete Estrogen Receptor Antagonist.ACS medicinal chemistry letters · 2026Article
- Bazedoxifene and Beyond: Identifying This SERM's Targets and Deciphering Its Molecular Mechanisms.Advances in pharmacological and pharmaceutical sciences · 2026Review
- A ternary switch model governing ERα ligand binding domain conformation.Nature communications · 2025Article
- Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor-positive breast cancer.JCI insight · 2025Article
- PARP-1 as a novel target in endocrine-resistant breast cancer.Journal of experimental & clinical cancer research : CR · 2025Article
- Article
- Molecular Mechanisms and Therapeutic Strategies to Overcome Resistance to Endocrine Therapy and CDK4/6 Inhibitors in Advanced ER+/HER2- Breast Cancer.International journal of molecular sciences · 2025Review
- Decoding estrogen receptor and GPER biology: structural insights and therapeutic advances in ERα-positive breast cancer.Frontiers in oncology · 2025Review
- Bazedoxifene as a Potential Cancer Therapeutic Agent Targeting IL-6/GP130 Signaling.Current oncology (Toronto, Ont.) · 2024Review
- Novel Treatment Strategies for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer.Journal of clinical medicine · 2024Review
- CDK4/6 Inhibition - Therapy Sequences and the Quest to Find the Best Biomarkers - an Overview of Current Programs.Geburtshilfe und Frauenheilkunde · 2024Article
- Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies.Endocrinology · 2024Review
- New generation estrogen receptor-targeted agents in breast cancer: present situation and future prospectives.Acta materia medica · 2024Article
- Liquid biopsy to tailor the treatment of advanced hormone receptor-positive breast cancer in the era of novel endocrine agents and CDK4/6-inhibitors.Annals of translational medicine · 2024Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Sean W FanningBen May Department for Cancer Research, University of Chicago, Chicago, United States.ORCID http://orcid.org/0000-0002-9428-0060
Rinath JeselsohnCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States.
Venkatasubramanian DharmarajanDepartment of Molecular Medicine, The Scripps Research Institute, Jupiter, United States.
Christopher G MayneDepartment of Biochemistry, College of Medicine, Center for Biophysics and Computational Biology, University of Illinois at Urbana-Champaign, Urbana, United States.ORCID https://orcid.org/0000-0001-8905-6569
Mostafa KarimiDepartment of Electrical and Computer Engineering, TEES-AgriLife Center for Bioinformatics and Genomic Systems Engineering, Texas A&M University, Texas, United States.
Gilles BuchwalterCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States.
René HoutmanPamGene International BV, 's-Hertogenbosch, The Netherlands.
Weiyi ToyHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, United States.
Colin E FowlerBen May Department for Cancer Research, University of Chicago, Chicago, United States.ORCID http://orcid.org/0000-0002-6281-2851
Ross HanBen May Department for Cancer Research, University of Chicago, Chicago, United States.
Muriel LainéBen May Department for Cancer Research, University of Chicago, Chicago, United States.
Kathryn E CarlsonDepartment of Chemistry, University of Illinois at Urbana-Champaign, Urbana, United States.
Teresa A MartinDepartment of Chemistry, University of Illinois at Urbana-Champaign, Urbana, United States.
Jason NowakDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States.
Jerome C NwachukwuDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, Jupiter, United States.ORCID http://orcid.org/0000-0003-4313-9187
David J HosfieldBen May Department for Cancer Research, University of Chicago, Chicago, United States.
Sarat ChandarlapatyHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, United States.ORCID https://orcid.org/0000-0003-4532-8053
Emad TajkhorshidDepartment of Biochemistry, College of Medicine, Center for Biophysics and Computational Biology, University of Illinois at Urbana-Champaign, Urbana, United States.ORCID http://orcid.org/0000-0001-8434-1010
Kendall W NettlesDepartment of Molecular Medicine, The Scripps Research Institute, Jupiter, United States.
Patrick R GriffinDepartment of Molecular Medicine, The Scripps Research Institute, Jupiter, United States.ORCID http://orcid.org/0000-0002-3404-690X
Yang ShenDepartment of Electrical and Computer Engineering, TEES-AgriLife Center for Bioinformatics and Genomic Systems Engineering, Texas A&M University, Texas, United States.ORCID http://orcid.org/0000-0002-1703-7796
John A KatzenellenbogenDepartment of Chemistry, University of Illinois at Urbana-Champaign, Urbana, United States.ORCID http://orcid.org/0000-0003-0914-0010
Myles BrownCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States.ORCID http://orcid.org/0000-0002-8213-1658
Geoffrey L GreeneBen May Department for Cancer Research, University of Chicago, Chicago, United States.ORCID http://orcid.org/0000-0001-6894-8728
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MUnraveling molecular and system-level mechanisms of human disease-associated protein mutationsR35GM124952 · NIGMS · TEXAS ENGINEERING EXPERIMENT STATION · PI Yang Shen · 2017 to 2026
$2.9MChemical, structural and molecular rules for fully antagonizing the estrogen receptorR01CA220284 · NCI · UNIVERSITY OF FLORIDA · PI KATZENELLENBOGEN, BENITA S, KATZENELLENBOGEN, JOHN A. · 2018 to 2022
$2.8MTherapeutic approaches to ER mutant breast cancerR01CA204999 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHANDARLAPATY, SARAT · 2017 to 2021
$2.0MElucidating and overcoming endocrine resistance driven by ESR1 mutationsK08CA191058 · NCI · DANA-FARBER CANCER INST · PI JESELSOHN, RINATH M. · 2015 to 2019
$886kCIHRNCI NIH HHS CCSG P30 CA08748NCI NIH HHS K08 CA191058NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA204999NCI NIH HHS R01 CA220284NIGMS NIH HHS R35 GM124952NIH HHS R01CA204999NIH HHS R01CA220284NIH HHS R35GM124952Susan G. Komen PDF14301382
Abstract
Acquired resistance to endocrine therapy remains a significant clinical burden for breast cancer patients. Somatic mutations in the
Indexed as
Breast NeoplasmsDrug Resistance, NeoplasmEstrogen Receptor alphaFemaleFulvestrantHumansIndolesLigandsMCF-7 CellsMutant ProteinsMutationPiperazinesProtein BindingProtein DomainsProtein Structure, SecondaryPyridinesbazedoxifeneESR1 protein, humanEstrogen Receptor alphaFulvestrantIndolesLigandsMutant ProteinspalbociclibPiperazinesPyridinesRaloxifene HydrochlorideSelective Estrogen Receptor ModulatorsTamoxifenacquired drug resistancebreast cancercancer biologyESR1 Somatic Mutationestrogen receptorhormone therapyhumanselective estrogen receptor Degrader
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.